CA2375826A1 - Novel epidermal growth factor receptor-binding compounds for positron emission tomography - Google Patents

Novel epidermal growth factor receptor-binding compounds for positron emission tomography Download PDF

Info

Publication number
CA2375826A1
CA2375826A1 CA002375826A CA2375826A CA2375826A1 CA 2375826 A1 CA2375826 A1 CA 2375826A1 CA 002375826 A CA002375826 A CA 002375826A CA 2375826 A CA2375826 A CA 2375826A CA 2375826 A1 CA2375826 A1 CA 2375826A1
Authority
CA
Canada
Prior art keywords
compound
group
fluorine
hydrogen
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375826A
Other languages
English (en)
French (fr)
Inventor
Eyal Mishani
Thomas Bonasera
Giuseppina Ortu
Yulia Rozen
Aviv Gazit
Alexander Levitzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375826A1 publication Critical patent/CA2375826A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002375826A 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography Abandoned CA2375826A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/322,979 1999-06-01
US09/322,979 US6126917A (en) 1999-06-01 1999-06-01 Epidermal growth factor receptor binding compounds for positron emission tomography
PCT/US2000/013749 WO2000072849A1 (en) 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Publications (1)

Publication Number Publication Date
CA2375826A1 true CA2375826A1 (en) 2000-12-07

Family

ID=23257276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375826A Abandoned CA2375826A1 (en) 1999-06-01 2000-05-19 Novel epidermal growth factor receptor-binding compounds for positron emission tomography

Country Status (7)

Country Link
US (1) US6126917A (enExample)
EP (1) EP1180034A4 (enExample)
JP (1) JP2003500450A (enExample)
AU (1) AU4857400A (enExample)
CA (1) CA2375826A1 (enExample)
IL (1) IL146805A0 (enExample)
WO (1) WO2000072849A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508343A (ja) * 2000-09-07 2004-03-18 ウイスコンシン　アラムニ　リサーチ　ファンデーション １７ｆ標識フルオロアルカンの合成
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1482983A4 (en) * 2001-06-14 2006-07-12 Yissum Res Dev Co NON-MYELOABLATIVE AND TOLEROGENIC TREATMENT BY TYRPHOSTINES
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
CA2533345A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
BRPI0414532B1 (pt) * 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
NO20035682D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
NO20035681D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
AU2006217738A1 (en) * 2005-02-26 2006-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) * 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
FR2926079B1 (fr) * 2008-01-03 2012-12-28 Commissariat Energie Atomique Procede de preparation d'un derive de purine marque, ledit derive et ses utilisations
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) * 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
EP2313397B1 (de) * 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8753605B2 (en) 2010-08-31 2014-06-17 The Board Of Trustees Of The Leland Stanford Junior University Imaging probes, methods of making imaging probes, and methods of imaging
CN103254140B (zh) * 2012-02-17 2016-02-17 北京师范大学 新型18f标记取代喹唑啉类化合物及其制备方法和肿瘤pet显像应用
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6172071B1 (en) * 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
AU5682799A (en) * 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
JP2002539262A (ja) * 1999-03-19 2002-11-19 パーカー ヒューズ インスティテュート キナゾリン化合物製剤および治療におけるその使用
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
US6126917A (en) 2000-10-03
EP1180034A1 (en) 2002-02-20
EP1180034A4 (en) 2003-05-14
IL146805A0 (en) 2002-07-25
WO2000072849A1 (en) 2000-12-07
JP2003500450A (ja) 2003-01-07
AU4857400A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
US6126917A (en) Epidermal growth factor receptor binding compounds for positron emission tomography
AU2002236194B2 (en) Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
Bonasera et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase
Dubost et al. Recent advances in synthetic methods for radioiodination
Maresca et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer
AU2002236194A1 (en) Radiolabeled Irreversible Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase and Their Use in Radioimaging and Radiotherapy
Mishani et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors
Kühnast et al. General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies
Mishani et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors
Jacobson et al. A rapid and simple one-step F-18 labeling of peptides
Shaul et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer
Elsinga et al. Synthesis and Evaluation of (S)-4-(3-(2 ‘-[11C] Isopropylamino)-2-hydroxypropoxy)-2 H-benzimidazol-2-one ((S)-[11C] CGP 12388) and (S)-4-(3-((1 ‘-[18F] Fluoroisopropyl) amino)-2-hydroxypropoxy)-2 H-benzimidazol-2-one ((S)-[18F] Fluoro-CGP 12388) for Visualization of β-Adrenoceptors with Positron Emission Tomography
US20060025430A1 (en) Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
Pandya et al. Propylene cross-bridged macrocyclic bifunctional chelator: A new design for facile bioconjugation and robust 64cu complex stability
CN105530961A (zh) 导入有[18f]氟甲基的脑神经炎症靶正电子发射断层扫描放射性示踪剂、其的合成及利用其的生物学结果评价方法
Cliffe A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT1A receptor PET radioligands
Lindsley et al. Diagnostic and therapeutic radiopharmaceuticals
Serdons et al. Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β
He et al. Quinazoline-2, 4 (1 H, 3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging
VanBrocklin et al. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes
Ait-Mohand et al. Development of bifunctional chelates bearing hydroxamate arms for highly efficient 64Cu radiolabeling
IL235122A (en) Quincosalin history is marked as radioactive drug applied in several ways and their starting materials
Nerella et al. Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review
AU2004270016A1 (en) Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
Wang et al. A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued